List of patient-reported quality of life surveys

Source: Wikipedia, the free encyclopedia.

This page lists patient-reported quality of life surveys used in the field of

trials. These surveys are patient-reported outcome measures, may be questionnaires or surveys
, and may be used to evaluate patient satisfaction, symptoms, disease state, or psychological well-being.

List
  1. The Adult Asthma Quality of Life Questionnaire (AQLQ) was developed at McMaster University in Ontario, Canada and was published in 1992.[15] It has since been used as a comparison tool[16] as well as a tool in clinical trials.[17][18]
  2. The Asthma Life Impact Scale (ALIS) measure was developed in 2010 by Galen Research.[19] It has been translated into 16 languages.[20]
  1. The Parents' Index of Quality of Life in Atopic Dermatitis (PiQOL-AD) measures the impact that atopic dermatitis has on quality of life, from the parents' perspective.[21] It has 28 items and was developed simultaneously in the United Kingdom, The Netherlands, Germany, Italy, Spain, France and the United States.[22] It has been utilised in several research studies investigating the treatment of paediatric atopic dermatitis with pimecrolimus.[23][24][25] and also in a research study regarding health-related quality of life measurement in children in Ibero-American countries.[26]
  2. The
    corticosteroids[31] and pimecrolimus.[32]
  • Oxford University. It was published in 1998.[33] It has been validated for use in assessing other non-surgical treatments for issues of the knee.[34]
  • Chickenpox. The Family Disruption Measure for Chickenpox was developed in 1994 by Galen Research.[35] It has been used in a study investigating rotavirus gastroenteritis.[36]
  • Chronic Otitis media. The Zurich Chronic Middle Ear Inventory (ZCMEI-21) has 21 questionnaires with answers as a 5-point Likert scale and measures health-related quality of life in chronic Otitis media with or without Cholesteatoma.[37] It has originally been developed in German and has been translated into several languages, including English,[38] Italian[39] and Japanese.[40]
  1. The Assessment of Quality of Life scales (AQoL) were psychometrically developed and refined over the past 30 years and are reliable and well-validated.[63] There are 4 instruments available; the AQoL-8D is the most comprehensive as it assesses HR-QoL across 8 domains - independent living, happiness, mental health, coping, relationships, self worth, pain, senses [64] (https://www.aqol.com.au).
  2. The Quality of Well-Being Scale (QWB) was developed in the 1970s, and a self-administered version called the QWB-SA was published in 1996.
    musculoskeletal disease,[68]
     amongst others.
  3. The EQ-5D is a generalised health-related quality of life measure which was developed in 1991 by the EuroQol Group.[69] It has five standard dimensions and has been translated into over 60 languages.[70] The EuroQoL has been extensively used in clinical trials, investigating a range of topics including overactive bladder,[71] attention deficit hyperactivity disorder[72] and denosumab for osteoporosis.[73]
  4. The
    erythropoiesis-stimulating agents,[77] glucocorticoid replacement therapy[78] and transcutaneous electrical nerve stimulation for tinnitus.[79]
  5. The
    giardia intestinalis,[82] breast cancer survivors[83] and Parkinson's disease.[84]
  6. The Sickness Impact Profile (SIP) was developed in 1997 by the Johns Hopkins University.[85] It consists of 136 items and has been adapted for strokes,[86] and ex-ICU patients.[87]
  7. The Health Utilities Index measures health status, health-related quality of life and produces utility scores.
    knee osteoarthritis,[90] urinary incontinence[91] and children who have been admitted to intensive care.[92]
  1. The Herpes Outbreak Impact Questionnaire (HOIQ) is designed to determine the impact of recurrent genital herpes outbreaks on a patient's life.[93] Its efficacy has been tested in an Australian clinical trial.[94]
  2. The Herpes Symptom Checklist (HSC) was developed alongside the HOIQ in order to assess daily symptoms of genital herpes outbreaks.[95] It was also used in an Australian clinical trial which tested the effectiveness of famciclovir.[96]
  3. The Recurrent genital herpes quality of life measure (RGHQoL) was developed in 1998 by Galen Research in order to assess the impact recurrent genital herpes has on quality of life.[97] It has been used in clinical trials investigating famciclovir,[98] suppressive antiviral therapy[99] and patient perspectives and quality of life.[100][101]

References

  1. ^ "ACQLI" (PDF). Galen-Research.com. Galen Research. Retrieved 11 November 2013.
  2. ^ Clinical trial number NCT00428090 for "Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease" at ClinicalTrials.gov
  3. ^ Clinical trial number NCT00348309 for "Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-2)" at ClinicalTrials.gov
  4. ^ Clinical trial number NCT00348140 for "Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-3)" at ClinicalTrials.gov
  5. S2CID 207301505
    .
  6. PMID 7829785
    .
  7. S2CID 35519046
    .
  8. PMID 23558043
    .
  9. PMID 19880202
    .
  10. PMID 12480664
    .
  11. PMID 19686597
    .
  12. PMID 17665483
    .
  13. PMID 11592375
    .
  14. PMID 12972490
    .
  15. PMID 1549827
    .
  16. S2CID 37156455
    .
  17. PMID 24176681
    .
  18. PMID 32212422
    .
  19. PMID 20053543
    .
  20. ^ Crawford SR. "Further Developments of the Asthma Life Impact Scale (ALIS)" (PDF). Galen-Research.com. Galen Research. Retrieved 14 October 2013.
  21. doi:10.1016/S1098-3015(10)62872-0
    .
  22. S2CID 21412583
    .
  23. S2CID 34465416
    .
  24. PMID 12093983
    .
  25. PMID 12170269
    .
  26. PMID 22433763
    .
  27. doi:10.1016/S1098-3015(10)62870-7
    .
  28. doi:10.1016/S1098-3015(10)62005-0
    .
  29. S2CID 20817434
    .
  30. S2CID 11139439
    .
  31. doi:10.1002/14651858.cd010080.pub2. If this is an intentional citation to a retracted paper, please replace {{Retracted}} with {{Retracted
    |intentional=yes}}.)
  32. doi:10.1016/S1098-3015(10)63408-0
    .
  33. PMID 9460955
    .
  34. S2CID 6498018
    .
  35. PMID 8171351
    .
  36. PMID 19200366. Open access icon
  37. S2CID 10107433
    .
  38. S2CID 58610511
    .
  39. S2CID 73436408
    .
  40. S2CID 46949869
    .
  41. PMID 22921317
    .
  42. ^ "Measures Database". Galen-Research.com. Galen Research. Retrieved 11 October 2013.
  43. PMID 20116755
    .
  44. S2CID 25950087
    .
  45. PMID 10122731
    .
  46. PMID 14639509
    .
  47. PMID 12393307
    .
  48. PMID 17725843. Open access icon
  49. PMID 16841626
    .
  50. PMID 15014623
    .
  51. S2CID 33216251
    .
  52. ^ "Epilepsy Surgery Inventory 55 Survey (ESI-55)". RAND.org. RAND Health. Retrieved 27 November 2013.
  53. S2CID 12205701
    .
  54. S2CID 566487
    .
  55. S2CID 27975316
    .
  56. PMID 11448327
    .
  57. PMID 21282568
    .
  58. PMID 21598855
    .
  59. S2CID 50961
    .
  60. S2CID 23273125
    .
  61. PMID 22012025
    .
  62. ^ "Measures Database". Galen-Research.com. Galen Research. Retrieved 20 November 2013.
  63. PMID 24271592
    .
  64. S2CID 2153470
    .
  65. ISBN 978-1-4129-7198-0
    .
  66. S2CID 1253643
    .
  67. S2CID 22869619
    .
  68. PMID 14872452
    .
  69. PMID 10158943
    .
  70. ^ "Euroqol EQ-5D (EQ-5D)". PROQOLID.org. Mapi Research Trust. Archived from the original on 31 January 2015. Retrieved 20 November 2013.
  71. PMID 24246044. Open access icon
  72. S2CID 20429564
    .
  73. PMID 24231131
    .
  74. PMID 6973203
    .
  75. PMID 3746178
    .
  76. PMID 3989783
    .
  77. PMID 22187314
    .
  78. S2CID 205286522
    .
  79. S2CID 43430574
    .
  80. ^ "36-Item Short Form Survey from the RAND Medical Outcomes Study". RAND.org. RAND. Retrieved 20 November 2013.
  81. S2CID 44458175
    .
  82. PMID 24206742
    .
  83. PMID 24249424
    .
  84. PMID 24247858
    .
  85. PMID 1200192
    .
  86. PMID 9368557
    .
  87. S2CID 6394744
    .
  88. PMID 14613568. Open access icon
  89. S2CID 37589566
    .
  90. S2CID 35129983
    .
  91. PMID 24055585
    .
  92. S2CID 23422052
    .
  93. doi:10.1016/S1098-3015(10)61938-9
    .
  94. PMID 18783390
    .
  95. PMID 18647252
    .
  96. doi:10.1016/j.jval.2011.08.193
    .
  97. S2CID 19058639
    .
  98. PMID 18621575
    .
  99. PMID 10754944
    .
  100. S2CID 24573908
    .
  101. S2CID 32358251
    .
  102. ^
    S2CID 11256536
    .
  103. PMID 21865066
    .
  104. PMID 20102556
    .
  105. S2CID 31044474
    .
  106. PMID 15613427
    .
  107. S2CID 31206757
    .
  108. S2CID 41098376
    .
  109. S2CID 207708239
    .
  110. PMID 24211750
    .
  111. S2CID 27610428
    .
  112. S2CID 23808987
    .
  113. S2CID 9406164
    .
  114. PMID 22113647
    .
  115. S2CID 44246726
    .
  116. S2CID 7459469
    .
  117. S2CID 208625075
    .
  118. ^ van Lokven T, Kempcke R, Ziemssen T, Meergans M (October 20, 2011). "Study design of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients (PANGAEA)". 5th Joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. Amsterdam, the Netherlands. Archived from the original on November 8, 2013. Retrieved October 9, 2013.
  119. ^ Cascione M, Wynn D, Agashivala N, McCague K, Pestreich L, Schofield L, Kim E, Barbato L (12 February 2013). "Patient-Reported Treatment Satisfaction, Reasons for Therapy Change, and Health-Related Quality of Life at Baseline from the Trial To Evaluate Patient OutComes, Safety and Tolerability of Fingolimod". Neurology. 80 (1). Retrieved 9 October 2013.
  120. S2CID 6838286
    .
  121. PMID 18512719
    .
  122. ^ "Treating painful hand osteoarthritis using low dose oral prednisolone- assessing short-term pain and imaging outcomes". EU Clinical Trials Register. European Medicines Agency. Retrieved 20 November 2013.
  123. ^ "An open label study to assess the effectiveness of oral methotrexate in reducing pain in knee osteoarthritis". EU Clinical Trials Register. European Medicines Agency. Retrieved 20 November 2013.
  124. ^ "HERO:Hydroxychloroquine Effectiveness in Reducing Symptoms of hand OA, a randomised, double-blind, placebo-controlled trial". Eu Clinical Trials Register. European Medicines Council. Retrieved 20 November 2013.
  125. S2CID 221801367
    .
  126. ^
    S2CID 20190839
    .
  127. PMID 23118412
    .
  128. PMID 22562983
    .
  129. doi:10.1186/ISRCTN21216199
    . Retrieved 2 October 2013.
  130. PMID 15641102
    .
  131. PMID 20595536
    .
  132. PMID 18718016. Open access icon
  133. S2CID 23830883
    .
  134. ^ "Measures Database". Galen-Research.com. Galen Research. Retrieved 2 October 2013.
  135. PMID 22291467
    .
  136. PMID 23496856. Open access icon
  137. PMID 20304507
    .
  138. PMID 18263674
    .
  139. S2CID 22163460
    .
  140. S2CID 26091210
    .
  141. ^ "Measures Database". Galen-Research.com. Galen Research. Retrieved 13 November 2013.
  142. ^ "Psoriasis: management of psoriasis" (PDF). NICE.org.uk. National Institute for Health and Care Excellence. Archived from the original (PDF) on 2013-11-13. Retrieved 13 November 2013.
  143. ^ "CAEB071C2201". ClinicalTrialsRegister.eu. EU Clinical Trials Register. Retrieved 13 November 2013.
  144. S2CID 26425942
    .
  145. PMID 14722205
    .
  146. PMID 17185324
    .
  147. ^ Clinical trial number NCT00427362 for "A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)" at ClinicalTrials.gov
  148. PMID 20440163
    .
  149. doi:10.1016/S1098-3015(10)75273-6
    .
  150. S2CID 23886698
    .
  151. PMID 23264550
    .
  152. PMID 22588761
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=List_of_patient-reported_quality_of_life_surveys&oldid=1192946459"